Protocols
3 protocol(s) meet the specified criteria
Drug: NAB PACLITAXEL
Protocol No.TitleStatus
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
LCCC1516A Randomized, Non-comparative Three Arm Phase II Trial of Sequential Consolidation with Pembrolizumab followed by Nab-paclitaxel, Sequential Consolidation with Nab-paclitaxel followed by Pembrolizumab and Concurrent Consolidation with Nab-paclitaxel and Pembrolizumab after Standard First-Line Induction Chemotherapy in Advanced NSCLCOpen
LCCC1621Multimodality Therapy with induction Carboplatin/nab-Paclitaxel/Durvalumab followed by surgical resection followed by risk-adapted adjuvant therapy for the treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Open